Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.
Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the evolution of daratumumab (Darzalex) administration in multiple myeloma.
Historically, daratumumab had a very long administration time, says Nagle. As patients tolerate the infusions, the administration time is shortened.
In May 2020, the FDA approved a subcutaneous formulation of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in adult patients with multiple myeloma.
Although patients are monitored for a period of time after receiving the subcutaneous regimen, the transition significantly shortens the administration time of daratumumab, which allows the agent to be more accessible to patients, concludes Nagle.